Cash-rich psychedelic stocks are cheap. They are also building value for investors -- at an accelerating rate.
Cash-rich psychedelic stocks are cheap. They are also building value for investors -- at an accelerating rate.
Numinus prepares for a Phase I clinical trial of its proprietary psilocybin extract.
Small Pharma announces receiving DTC Eligibility and its OTCQB listing to broaden liquidity and increase access for U.S. investors.
Cybin has completed its 74th pre-clinical study and anticipates commencing human clinical studies in early 2022.
Compass Pathway's fourth U.S. patent covers its Form A hydrate psilocybin, and is the first patent for this formulation.
Field Trip is adding three new clinics to its network, with two of the three already open and the third opening imminently.
Small Pharma commences enrolling patients for its Phase IIa DMT-based clinical trial aimed at treating Major Depressive Disorder.
Drug development through the formal clinical trials process is slow and expensive. Real World Evidence (RWE) drug development is fast and cheap. Have we got your attention yet?
Levitee Labs announces a partnership with Adracare Inc., a subsidiary of Well Health Technologies (WELL), to build out a digital therapeutics platform.
The "crippling labor shortages" plaguing the U.S. economy are directly attributable to the Mental Health Crisis. Psychedelic medicine is the only answer.
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now